Can a simple blood test track brain tumor treatment? new study investigates
NCT ID NCT06610682
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase trial is looking at whether tumor DNA found in blood and spinal fluid can help monitor how well treatment is working in people with a specific type of brain tumor (BRAF-mutant glioma). About 24 participants whose tumors have not responded to prior therapies will receive plixorafenib alone or with retifanlimab. Researchers will collect samples before and during treatment to see if changes in ctDNA levels match tumor shrinkage or growth on MRI scans.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- plixorafenib (a drug taken by mouth) and retifanlimab (an immunotherapy given by infusion)
- What this could lead to
- If successful, this could help doctors use ctDNA levels to monitor how well treatments are working in BRAF-mutant glioma, potentially guiding future care.
- What could go wrong
- This is a very early, small study (24 people) focused on measuring ctDNA, not on proving the treatment works. The approach may not reliably track disease or improve outcomes.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BRAF V600E MUTATION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Johns Hopkins
RECRUITINGBaltimore, Maryland, 21231, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.